Dual Inhibition of LAG-3 and PD-1 in Patients with Previously Untreated Metastatic or Unresectable Melanoma
RELATIVITY-047 validates LAG-3 as the third immune checkpoint inhibition pathway of clinical benefit
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1651 results
EMA Recommends Extension of Indications for Tegafur
New indication concerns the treatment of patients with metastatic colorectal cancer for whom due to toxicity is not possible to continue treatment with another fluoropyrimidine
EMA Recommends Granting a Marketing Authorisation for Tepotinib
It is indicated for the treatment of adult patients with advanced NSCLC harbouring alterations leading to METex14 skipping
Nivolumab Does Not Prolong Overall Survival Compared with Sorafenib In First-Line Treatment for Advanced Hepatocellular Carcinoma
Findings from the CheckMate 459 study
Tisagenlecleucel Is Safe and Effective in Pretreated Patients with Relapsed/Refractory Follicular Lymphoma
Findings from the ELARA study
EMA Recommends Extension of Indications for Lorlatinib
New indication concerns the treatment of adult patients with ALK positive advanced NSCLC previously not treated with an ALK inhibitor
EMA Recommends Granting a Marketing Authorisation for Enfortumab Vedotin for the Treatment of Urothelial Cancer
An antibody drug conjugate induces cytotoxicity in cancer cells by binding to the nectin-4
FDA Approves Pafolacianine for Identifying Malignant Ovarian Cancer Lesions
An optical imaging agent that targets folate receptor is an adjunct for interoperative identification of malignant lesions in adult patients with ovarian cancer
A Remarkable Group of Patients with Haematological Disorders with No or Low Immune Response After Second COVID-19 Vaccine Dose
The rate of negative antibody results highest among patients with lymphoid neoplasms
Six Months Immunogenicity of COVID-19 mRNA-based Vaccine in Patients with Actively Treated Solid Malignancies
Updated results of the Vax-On study favour the third vaccine dose for actively treated patients with cancer
Limited Effect of Endocrine Therapy on Distant Metastasis-Free Interval in Patients with Stage I Low-Risk Breast Cancer, but Fewer Breast Cancer Events
Findings from an exploratory subgroup analysis of patients included in the MINDACT study
FDA Approves Rituximab Plus Chemotherapy for Paediatric Cancer Indications
Efficacy was evaluated in Inter-B-NHL Ritux 2010 global randomised study